Cargando…

Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex

Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Krogsgaard, Michelle, Wucherpfennig, Kai W., Canella, Barbara, Hansen, Bjarke E., Svejgaard, Arne, Pyrdol, Jason, Ditzel, Henrik, Raine, Cedric, Engberg, Jan, Fugger, Lars
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193136/
https://www.ncbi.nlm.nih.gov/pubmed/10770805
_version_ 1782147399641202688
author Krogsgaard, Michelle
Wucherpfennig, Kai W.
Canella, Barbara
Hansen, Bjarke E.
Svejgaard, Arne
Pyrdol, Jason
Ditzel, Henrik
Raine, Cedric
Engberg, Jan
Fugger, Lars
author_facet Krogsgaard, Michelle
Wucherpfennig, Kai W.
Canella, Barbara
Hansen, Bjarke E.
Svejgaard, Arne
Pyrdol, Jason
Ditzel, Henrik
Raine, Cedric
Engberg, Jan
Fugger, Lars
author_sort Krogsgaard, Michelle
collection PubMed
description Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodies specific for defined HLA-DR2–peptide complexes may therefore be valuable tools for studying antigen presentation in MS. We have used phage display technology to select HLA-DR2–peptide-specific antibodies from HLA-DR2–transgenic mice immunized with HLA-DR2 molecules complexed with an immunodominant myelin basic protein (MBP) peptide (residues 85–99). Detailed characterization of one clone (MK16) demonstrated that both DR2 and the MBP peptide were required for recognition. Furthermore, MK16 labeled intra- and extracellular HLA-DR2–MBP peptide complexes when antigen-presenting cells (APCs) were pulsed with recombinant MBP. In addition, MK16 inhibited interleukin 2 secretion by two transfectants that expressed human MBP–specific T cell receptors. Analysis of the structural requirement for MK16 binding demonstrated that the two major HLA-DR2 anchor residues of MBP 85–99 and the COOH-terminal part of the peptide, in particular residues Val-96, Pro-98, and Arg-99, were important for binding. Based on these results, the antibody was used to determine if the HLA-DR2–MBP peptide complex is presented in MS lesions. The antibody stained APCs in MS lesions, in particular microglia/macrophages but also in some cases hypertrophic astrocytes. Staining of APCs was only observed in MS cases with the HLA-DR2 haplotype but not in cases that carried other haplotypes. These results demonstrate that HLA-DR2 molecules in MS lesions present a myelin-derived self-peptide and suggest that microglia/macrophages rather than astrocytes are the predominant APCs in these lesions.
format Text
id pubmed-2193136
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21931362008-04-16 Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex Krogsgaard, Michelle Wucherpfennig, Kai W. Canella, Barbara Hansen, Bjarke E. Svejgaard, Arne Pyrdol, Jason Ditzel, Henrik Raine, Cedric Engberg, Jan Fugger, Lars J Exp Med Original Article Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leukocyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–restricted presentation of central nervous system–derived antigens is important in the disease process. Antibodies specific for defined HLA-DR2–peptide complexes may therefore be valuable tools for studying antigen presentation in MS. We have used phage display technology to select HLA-DR2–peptide-specific antibodies from HLA-DR2–transgenic mice immunized with HLA-DR2 molecules complexed with an immunodominant myelin basic protein (MBP) peptide (residues 85–99). Detailed characterization of one clone (MK16) demonstrated that both DR2 and the MBP peptide were required for recognition. Furthermore, MK16 labeled intra- and extracellular HLA-DR2–MBP peptide complexes when antigen-presenting cells (APCs) were pulsed with recombinant MBP. In addition, MK16 inhibited interleukin 2 secretion by two transfectants that expressed human MBP–specific T cell receptors. Analysis of the structural requirement for MK16 binding demonstrated that the two major HLA-DR2 anchor residues of MBP 85–99 and the COOH-terminal part of the peptide, in particular residues Val-96, Pro-98, and Arg-99, were important for binding. Based on these results, the antibody was used to determine if the HLA-DR2–MBP peptide complex is presented in MS lesions. The antibody stained APCs in MS lesions, in particular microglia/macrophages but also in some cases hypertrophic astrocytes. Staining of APCs was only observed in MS cases with the HLA-DR2 haplotype but not in cases that carried other haplotypes. These results demonstrate that HLA-DR2 molecules in MS lesions present a myelin-derived self-peptide and suggest that microglia/macrophages rather than astrocytes are the predominant APCs in these lesions. The Rockefeller University Press 2000-04-17 /pmc/articles/PMC2193136/ /pubmed/10770805 Text en © 2000 The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Original Article
Krogsgaard, Michelle
Wucherpfennig, Kai W.
Canella, Barbara
Hansen, Bjarke E.
Svejgaard, Arne
Pyrdol, Jason
Ditzel, Henrik
Raine, Cedric
Engberg, Jan
Fugger, Lars
Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title_full Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title_fullStr Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title_full_unstemmed Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title_short Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex
title_sort visualization of myelin basic protein (mbp) t cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (hla)-dr2–mbp 85–99 complex
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193136/
https://www.ncbi.nlm.nih.gov/pubmed/10770805
work_keys_str_mv AT krogsgaardmichelle visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT wucherpfennigkaiw visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT canellabarbara visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT hansenbjarkee visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT svejgaardarne visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT pyrdoljason visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT ditzelhenrik visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT rainecedric visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT engbergjan visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex
AT fuggerlars visualizationofmyelinbasicproteinmbptcellepitopesinmultiplesclerosislesionsusingamonoclonalantibodyspecificforthehumanhistocompatibilityleukocyteantigenhladr2mbp8599complex